AUG 30, 2016 08:00 AM PDT
From urine to the study of metabolic disease - A patient-driven strategy to decipher PCSK9 roles and functions.
Presented at the Gibco 24 Hours of Stem Cells virtual event Virtual Event
1 1 71

  • Young Investigator, l'institut du thorax INSERM, France
      After achieving his PhD in Bordeaux under the direction of Dr. Jean Rosenbaum, Dr. Si-Tayeb joined the research team of Professor Stephen Duncan at the Medical College of Wisconsin, Milwaukee, WI. Together, they developed a strategy to direct patient-derived hiPS cells to become liver cells and study metabolic diseases, including familial hypercholesterolemia. Back in France, and after a short passage in Paris, Dr. Si-Tayeb joined the "institut du thorax" in Nantes in order to work more specifically on PCSK9 together with Prof Bertrand Cariou, an MD-PhD who specializes in endocrinology who participated in clinical trials on PCSK9 inhibition and Dr Cédric Le May specialized in lipid metabolism. Dr. Si-Tayeb and his team showed how it is possible to isolate cells from urine samples, amplify them, reprogram them into hiPS cells and then direct them to become liver cells. Starting with urine samples of patients from the Nantes area, they showed that it was possible to model the effects of PCSK9 mutations on LDL uptake in a petri dish.

    In the last 10 years, PCSK9 emerged as a promising target for the treatment of autosomal dominant hypercholesterolemia (ADH). With the emergence of induced pluripotent stem (hiPS) cells and following differentiation protocols as a model for human pathology studies, we recently demonstrated the modeling of ADH due to mutations in the LDLR gene.  Our strategy to better understand the role of PCSK9 included reprogramming somatic cells from patients carrying the S127R mutation into hiPS cells, differentiate these cells into hepatocytes and characterize the intracellular impact of the mutated form of PCSK9.
    To facilitate our strategy, we developed the isolation, culture, amplification and reprogramming of progenitor cells derived from urine samples (UCell). After reprogramming the hiPS cells (UhiPS), showed similar characteristics to hiPS cells classically reprogrammed from skin fibroblast. Through differentiation of the UhiPS cells hepatocytes were obtained that secrete PCSK9, internalized LDL particles and respond positively to statin treatments.To validate our model, in addition to generating hiPS cells carrying the PCSK9-GOF S127R, we reprogrammed cells from a patient carrying the PCSK9-LOF R104C/V114A and showed a spontaneously low level of LDL-cholesterol. Compared to control cells, UhiPS-S127R and –R104C/V114A differentiated in a comparable manner toward hepatocytes. In our hands, while hepatocytes carrying the S127R mutation showed a lower ability to uptake LDL, hepatocytes carrying the R104C/V114A mutations displayed the inverse, when compared to control cells. In addition, cells derived from the hypercholesterolemic patient responded positively to statin treatments, at a level comparable to the clinical response of patients carrying the same S127R mutation. Altogether, we demonstrated that differentiated hiPS cells are a relevant model to decipher PCSK9 functions and patient-derived urine samples represent a convenient source of somatic cells for such study.

    Show Resources
    Loading Comments...
    Show Resources